Author(s):
Venkatesh Anand Iyer, Golam Md Mowazzim, Sukhen Majhi, Jaipal Meena, Manjula Kiran, Farha, Shikha Yadav, Harit Kasana
Email(s):
hkasana@nib.gov.in
DOI:
10.52711/0974-360X.2026.00413 
Address:
Venkatesh Anand Iyer1, Golam Md Mowazzim1, Sukhen Majhi, Jaipal Meena, Manjula Kiran, Farha, Shikha Yadav, Harit Kasana*
National Institute of Biologicals, Sector - 62, Noida.
*Corresponding Author
Published In:
Volume - 19,
Issue - 6,
Year - 2026
ABSTRACT:
Rabies endures as a significant global public health problem, with India carrying a disproportionate burden of the illness. Despite breakthroughs in medical research and the availability of effective vaccines, rabies continues to claim thousands of lives annually, with children being particularly vulnerable. This paper stresses the function of Quality Control (QC) for controlling rabies in India through analyzing the quality of vaccines offered by different manufacturers. It also underlines the crucial need for widespread education, comprehensive preventative measures, and enhanced access to post-exposure prophylaxis (PEP) to safeguard vulnerable people. The development and availability of safe and efficient vaccines, hold promise for rabies prevention. Additionally, effective regulatory frameworks, led by organizations like the Central Drugs Standard Control Organisation (CDSCO), supported by multiple pharmacopoeias, play a significant role in guaranteeing the safety and efficacy of vaccinations.
Cite this article:
Venkatesh Anand Iyer, Golam Md Mowazzim, Sukhen Majhi, Jaipal Meena, Manjula Kiran, Farha, Shikha Yadav, Harit Kasana. Advancing Rabies Control in India: The Crucial Role of QC in Vaccine Provision and Public Health Initiatives. Research Journal Pharmacy and Technology. 2026;19(6):2894-0. doi: 10.52711/0974-360X.2026.00413
Cite(Electronic):
Venkatesh Anand Iyer, Golam Md Mowazzim, Sukhen Majhi, Jaipal Meena, Manjula Kiran, Farha, Shikha Yadav, Harit Kasana. Advancing Rabies Control in India: The Crucial Role of QC in Vaccine Provision and Public Health Initiatives. Research Journal Pharmacy and Technology. 2026;19(6):2894-0. doi: 10.52711/0974-360X.2026.00413 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-6-70
REFERENCES:
1. Radhakrishnan S, Vanak AT, Nouvellet P, Donnelly CA. Rabies as a public health concern in India—a historical perspective. Trop Med Infect Dis. 2020; 5(4): 162. doi:10.3390/tropicalmed5040162
2. World Health Organization. Rabies. World Health Organization. Published September 28, 2018. Accessed February 25, 2024. https://www.who.int/rabies/en/
3. Giraudet CSE, Liu K, McElligott AG, Cobb M. Are children and dogs best friends? A scoping review to explore the positive and negative effects of child-dog interactions. PeerJ. 2022; 10: e14532. Published December 19, 2022. doi:10.7717/peerj.14532
4. Lodha L, Manoor Ananda A, Mani RS. Rabies control in high-burden countries: role of universal pre-exposure immunization. Lancet Reg Health Southeast Asia. 2023; 19: 100258. Published August 1, 2023. doi:10.1016/j.lansea.2023.100258
5. Natesan K, Isloor S, Vinayagamurthy B, et al. Developments in rabies vaccines: the path traversed from Pasteur to the modern era of immunization. Vaccines (Basel). 2023; 11(4): 756. Published March 29, 2023. doi:10.3390/vaccines11040756
6. Ravish HS, Vijayashankar V, Madhusudana SN, et al. Safety and immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post-exposure prophylaxis. Hum Vaccin Immunother. 2014; 10(8): 2433-2437. doi:10.4161/hv.29403
7. Moulenat T, Petit C, Bosch Castells V, Houillon G. Purified Vero cell rabies vaccine (PVRV, Verorab®): a systematic review of intradermal use between 1985 and 2019. Trop Med Infect Dis. 2020; 5(1): 40. Published March 7, 2020. doi:10.3390/tropicalmed5010040
8. Smith J, Lipsitch M, Almond JW. Vaccine production, distribution, access, and uptake. Lancet. 2011; 378(9789): 428-438. doi:10.1016/S0140-6736(11)60478-9
9. Central Drugs Standard Control Organization. What's new. Published January 1, 2021. Accessed February 25, 2024. https://cdsco.gov.in/opencms/opencms/en/Home/
10. Government of India. The Drugs and Cosmetics Act and Rules. 8. Published 1940. Updated 2016. Accessed September 10, 2022.
11. Kasana H, Chander H, Mathur A. A systematic review of regulatory requirements of biosimilar products: WHO, India, European Union and USFDA. Res J Pharm Technol. 2024; 17(5): 2413-0. doi:10.52711/0974-360X.2024.00378
12. Amaq Fadholly, Arif N. M. Ansori, Viol D. Kharisma, Jola Rahmahani, Martia R. Tacharina. Immunobioinformatics of Rabies Virus in Various Countries of Asia: Glycoprotein Gene. Research J. Pharm. and Tech. 2021; 14(2): 883-886. doi: 10.5958/0974-360X.2021.00157.8
13. Sr. Joseena, Jain Jacob, Aleena Paul, Amrutha Vijayan, Ankitha A, Ansu Maria Reeni, Jismi K Shaji, Teena Thomas. A Study to Assess the Effectiveness of a Planned Teaching Awareness Programme on Rabies and Management of Dog Bite among students of selected high school in Kottayam District, Kerala. Asian Journal of Nursing Education and Research. 2024; 14(4): 263-7. doi: 10.52711/2349-2996.2024.00052
14. Fooks AR, Banyard AC, Horton DL, et al. Current status of rabies and prospects for elimination. Lancet. 2014; 384(9951): 1389-1399. doi:10.1016/S0140-6736(13)62707-5
15. Singh R, Singh KP, Cherian S, et al. Rabies – epidemiology, pathogenesis, public health concerns and advances in diagnosis and control: a comprehensive review. Vet Q. 2017; 37(1): 212-251. doi:10.1080/01652176.2017.1343516
16. World Health Organization. Rabies vaccines: WHO position paper, April 2018 - Summary. Accessed August 8, 2024. https://cdn.who.int/media/docs/default-source/immunization/position_paper_documents/rabies/pp-rabies-summary-2018.pdf
17. Davis BM, Rall GF, Schnell MJ. Everything you always wanted to know about rabies virus (but were afraid to ask). Annu Rev Virol. 2015; 2(1): 451-471. doi:10.1146/annurev-virology-100114-055157
18. Fermin G. Virion structure, genome organization, and taxonomy of viruses. In: Viruses. 2018: 17-54. doi:10.1016/B978-0-12-811257-1.00002-4
19. Burrell CJ, Howard CR, Murphy FA. Virion structure and composition. In: Fenner and White's Medical Virology. 2017: 27-37. doi:10.1016/B978-0-12-375156-0.00003-5
20. Más V, Melero JA. Entry of enveloped viruses into host cells: membrane fusion. Subcell Biochem. 2013; 68: 467-487. doi:10.1007/978-94-007-6552-8_16
21. Albertini AA, Ruigrok RW, Blondel D. Rabies virus transcription and replication. Adv Virus Res. 2011; 79: 1-22. doi:10.1016/B978-0-12-387040-7.00001-9
22. Payne S. Introduction to RNA viruses. In: Viruses. 2017: 97-105. doi:10.1016/B978-0-12-803109-4.00010-6
23. Yin J, Wang X, Mao R, et al. Research advances on the interactions between rabies virus structural proteins and host target cells: accrued knowledge from the application of reverse genetics systems. Viruses. 2021; 13(11): 2288. Published November 16, 2021. doi:10.3390/v13112288
24. Fadholly A, Ansori ANM, Kharisma VD, et al. Immunobioinformatics of rabies virus in various countries of Asia: glycoprotein gene. Res J Pharm Technol. 2021; 14(2): 883-886. doi:10.5958/0974-360X.2021.00157.8
25. Plavec Z, Pöhner I, Poso A, Butcher SJ. Virus structure and structure-based antivirals. Curr Opin Virol. 2021; 51: 16-24. doi:10.1016/j.coviro.2021.09.005
26. Maginnis MS. Virus-receptor interactions: the key to cellular invasion. J Mol Biol. 2018; 430(17): 2590-2611. doi:10.1016/j.jmb.2018.06.024
27. California Department of Public Health, Veterinary Public Health Section. California Compendium of Rabies Control and Prevention. California Department of Public Health; 2012. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/VPHS.aspx
28. Zandi F, Goshadrou F, Meyfour A, Vaziri B. Rabies infection: an overview of lyssavirus-host protein interactions. Iran Biomed J. 2021; 25(4): 226-242. doi:10.52547/ibj.25.4.226
29. Schnell M, McGettigan J, Wirblich C, et al. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol. 2010; 8: 51-61. doi:10.1038/nrmicro2260
30. Iwasaki A, Omer SB. Why and how vaccines work. Cell. 2020; 183(2): 290-295. doi:10.1016/j.cell.2020.09.040
31. Raghotham S, Balamuralidhara V, Kamireddy Karuna. Registration requirement and approval procedure of vaccines in Saudi Arabia. Res J Pharm Technol. 2019; 12(9): 4531-4538. doi:10.5958/0974-360X.2019.00780.7
32. Visweswaran V, Binoy A, Sreenivas A, et al. Vaccines-pillars of preventive health. Res J Pharm Technol. 2017; 10(9): 3205-3210. doi:10.5958/0974-360X.2017.00569.8
33. Hyam Raouf Al-Hamamy. COVID-19: Immune response. Research Journal of Pharmacy and Technology. 2022; 15(1): 467-0. doi: 10.52711/0974-360X.2022.00076
34. Dhanashri U. Gadhave, Puja S. Gaikwad, Nayana V. Pimpodkar, Swati B. Udugade. DNA vaccines: A hope full ray in Immunology. Asian J. Res. Pharm. Sci. 2015; 5(2): 126-131. doi: 10.5958/2231-5659.2015.00020.X
35. Saloni S. Chhajed, Mayuri V. Mali, Azam Z. Shaikh, S. P. Pawar, Ritik. S. Jain. Cancer: Immunology and Immunotharapy. Research Journal of Pharmacology and Pharmacodynamics. 2022; 14(3): 159-4. doi: 10.52711/2321-5836.2022.00027
36. Moulenat T, Petit C, Bosch Castells V, Houillon G. Purified Vero cell rabies vaccine (PVRV, Verorab®): a systematic review of intradermal use between 1985 and 2019. Trop Med Infect Dis. 2020; 5(1): 40. Published March 7, 2020. doi:10.3390/tropicalmed5010040
37. Hicks DJ, Fooks AR, Johnson N. Developments in rabies vaccines. Clin Exp Immunol. 2012; 169(3): 199-204. doi:10.1111/j.1365-2249.2012.04592.x
38. Ahmad N, Nawi AM, Jamhari MN, et al. Post-exposure prophylactic vaccination against rabies: a systematic review. Iran J Public Health. 2022; 51(5): 967-977. doi:10.18502/ijph.v51i5.9412
39. Cabasso VJ, Loofbourow JC, Roby RE, Anuskiewicz W. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ. 1971; 45(3): 303-315.
40. World Health Organization. Accessed August 8, 2024. https://iris.who.int/bitstream/handle/10665/341942/9789240022379-eng.pdf
41. Natesan K, Isloor S, Vinayagamurthy B, Ramakrishnaiah S, Doddamane R, Fooks AR. Developments in rabies vaccines: the path traversed from Pasteur to the modern era of immunization. Vaccines (Basel). 2023; 11(4): 756. Published March 29, 2023. doi:10.3390/vaccines11040756
42. Centers for Disease Control and Prevention. Accessed August 8, 2024. https://www.cdc.gov/mmwr/pdf/rr/rr5703.pdf
43. World Health Organization. Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. In WHO Technical Report Series: Vol. No 941. Published 2007. https://cdn.who.int/media/docs/default-source/biologicals/vaccine-quality/recommendations-for-inactivated-rabies-vaccine-for-human-use-produced-in-cell-substrates-and-embryonated-eggs7e915689-65a0-459a-9ec0-0a377c372e4a.pdf
44. Centers for Disease Control and Prevention. Rabies post-exposure prophylaxis. Published June 20, 2024. https://www.cdc.gov/rabies/hcp/prevention-recommendations/post-exposure-prophylaxis.html
45. World Health Organization. Protocol for a well-performed rabies post-exposure prophylaxis delivery. Accessed August 8, 2024. https://iris.who.int/bitstream/handle/10665/376632/B09018-eng.pdf
46. Chao TY, Zhang SF, Chen L, Tsao E, Rupprecht CE. In vivo efficacy of SYN023, an anti-rabies monoclonal antibody cocktail, in post-exposure prophylaxis animal models. Trop Med Infect Dis. 2020; 5(1): 31. Published February 21, 2020. doi:10.3390/tropicalmed5010031
47. Centers for Disease Control and Prevention. Rabies prophylaxis of people. Accessed August 8, 2024. http://publichealth.lacounty.gov/vet/rabiesmanualpdfs/pplerabvac.pdf
48. Sudarshan MK, Ashwath Narayana DH, Mahendra BJ, et al. Comprehensive multi-state study on rabies in India [report]. Published 2021. http://apcri.in/pdf/WHO-APCRI%20Rabies%20Survey,%202017%20-%20Final%20Report.pdf
49. Trends GSA. Human rabies immune globulin (HRIG) market report | global forecast from 2024-2032. Published April 17, 2024. https://www.linkedin.com/pulse/human-rabies-immune-globulin-hrig-market-0i9je/
50. Motorcycles market size, share and trends analysis report by type (on-road motorcycles, off-road motorcycles, scooters), by region, and segment forecasts, 2022-2028. Accessed August 8, 2024. https://www.grandviewresearch.com/industry-analysis/motercycles-market-report
51. Masters MR. Equine rabies immunoglobulin (ERIG) market is expanding at a 4.4% CAGR, aiming for a market size of USD 0.47 billion by 2030. Published November 7, 2024. https://www.linkedin.com/pulse/equine-rabies-immunoglobulin-erig-market-expanding-2ppee/
52. Research Reports World [RRW]. Equine rabies immunoglobulin (ERIG) market [2024-2032] new insight - 88 pages report. Published May 14, 2024. https://www.linkedin.com/pulse/equine-rabies-immunoglobulin-erig-market-2024-2032-lel1c/Wood C. In-process control testing. Sep Sci Technol. 2010; 10: 397-427. doi:10.1016/B978-0-12-375680-0.00010-3
53. Lange R, Schnor T. Product quality, quality control and validation. In: Le Brun P, Crauste-Manciet S, Krämer I, Smith J, Woerdenbag H, eds. Practical Pharmaceutics. Cham: Springer; 2023. doi:10.1007/978-3-031-20298-8_32
54. Dumpa N, Goel K, Guo Y, et al. Stability of vaccines. AAPS PharmSciTech. 2019; 20: 42. doi:10.1208/s12249-018-1254-2
55. Huynh-Ba K. Analytical method validation for quality assurance and process validation professionals. Published October 13, 2020. https://www.americanpharmaceuticalreview.com/Featured-Articles/569734-Analytical-Method-Validation-for-Quality-Assurance-and-Process-Validation-Professionals/
56. George B, Kulkarni SK, Kshirsagar NA. Regulatory requirements and quality standards in India’s clinical trials journey. In: Dikshit M, ed. Drug Discovery and Drug Development. Singapore: Springer; 2021. doi:10.1007/978-981-15-8002-4_12
57. About the U.S. Pharmacopeia. Accessed August 8, 2024. https://www.usp.org/about
58. European Pharmacopoeia Online. Accessed August 8, 2024. https://pheur.edqm.eu/home
59. Home - British Pharmacopoeia. Accessed August 8, 2024. https://www.pharmacopoeia.com/
60. Japanese Pharmacopoeia 18th Edition. Pharmaceuticals and Medical Devices Agency. Accessed August 8, 2024. https://www.pmda.go.jp/english/rs-sb-std/standards-development/jp/0029.html
61. Cisema-Jacky. Chinese pharmacopoeia 2020 - English ed. issued in March 2023. CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung. Published April 26, 2023. https://www.cisema.com/en/chinese-pharmacopoeia-2020-edition-official-english-translation/
62. Marshal V, Baylor NW. Food and Drug Administration regulation and evaluation of vaccines. Centers for Disease Control and Prevention. Published May 2011. Accessed February 26, 2024. https://www.cdc.gov/vaccines/basics/test-approve.html
63. Meissner HC. Understanding vaccine safety and the roles of the FDA and the CDC. N Engl J Med. 2022; 386(17): 1638-1645. doi:10.1056/NEJMra2200583
64. Elveborg S, Monteil VM, Mirazimi A. Methods of inactivation of highly pathogenic viruses for molecular, serology or vaccine development purposes. Pathogens. 2022; 11(2): 271. Published February 19, 2022. doi:10.3390/pathogens11020271
65. Sanyal G. Development of functionally relevant potency assays for monovalent and multivalent vaccines delivered by evolving technologies. NPJ Vaccines. 2022; 7(1): 50. Published May 5, 2022. doi:10.1038/s41541-022-00470-4
66. Romiszowski AJ. Interdepartmental Communication and Collaboration. Educational Technology Publications; 1996.
67. Shapiro MH, Gebhart FH. Pharmaceutical Quality Control and Regulatory Compliance. Marcel Dekker Inc; 1998.